AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
The regulatory authority in Japan has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination for…